Pharmacokinetics and dose selection of the 2-and 3-direct acting antiviral combination of AL-335 and odalasvir with/without simeprevir in hepatitis C virus-infected patients

被引：0
|
作者：
Kakuda, Thomas [1 ]
Ouwerkerk-Mahadevan, Sivi [2 ]
Ackaert, Oliver [2 ]
Valade, Elodie [2 ]
McClure, Matthew W. [1 ]
Westland, C. [1 ]
Vuong, J. [1 ]
Gane, Edward J. [3 ]
Fry, J. [1 ]
Chanda, Sushmita M. [1 ]
机构：
[1] Alios BioPharma Inc, San Francisco, CA USA
[2] Janssen Pharmaceut NV, Janssen Res & Dev, Beerse, Belgium
[3] Univ Auckland, New Zealand Liver Transplant Unit, Auckland, New Zealand
来源：
HEPATOLOGY | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1192
引用
收藏
页码：642A / 643A
页数：2
相关论文
共 40 条
  • [31] Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong
    Yuen, Man-Fung
    Liu, Sze-Hang
    Seto, Wai-Kay
    Mak, Lung-Yi
    Corman, Shelby L.
    Hsu, Danny C.
    Lee, Mary Y. K.
    Khan, Tsz K.
    Puenpatom, Amy
    DIGESTIVE DISEASES AND SCIENCES, 2021, 66 (04) : 1315 - 1326
  • [32] JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study
    Takehara, Tetsuo
    Chayama, Kazuaki
    Kurosaki, Masayuki
    Yatsuhashi, Hiroshi
    Tanaka, Yasuhito
    Hiramatsu, Naoki
    Sakamoto, Naoya
    Asahina, Yasuhiro
    Nozaki, Akito
    Nakanom, Toshikazu
    Hagiwara, Yosuke
    Shimizu, Hiroko
    Yoshida, Hiroki
    Huang, Yuhan
    Biermer, Michael
    Vijgen, Leen
    Hayashi, Norio
    JOURNAL OF GASTROENTEROLOGY, 2020, 55 (06) : 640 - 652
  • [33] Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2and 3 in northwest China
    Ying Yang
    Feng-Ping Wu
    Wen-Jun Wang
    Juan-Juan Shi
    Ya-Ping Li
    Xin Zhang
    Shuang-Suo Dang
    World Journal of Gastroenterology, 2019, (44) : 6551 - 6560
  • [34] JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study
    Tetsuo Takehara
    Kazuaki Chayama
    Masayuki Kurosaki
    Hiroshi Yatsuhashi
    Yasuhito Tanaka
    Naoki Hiramatsu
    Naoya Sakamoto
    Yasuhiro Asahina
    Akito Nozaki
    Toshikazu Nakano
    Yosuke Hagiwara
    Hiroko Shimizu
    Hiroki Yoshida
    Yuhan Huang
    Michael Biermer
    Leen Vijgen
    Norio Hayashi
    Journal of Gastroenterology, 2020, 55 : 640 - 652
  • [35] NS3 inhibition coupled with potent direct acting antiviral combinations leads to enhanced hepatitis C virus specific immunity in hepatitis C virus-human immunodeficiency virus co-infected patients
    Shrivastava, S.
    Bhatta, M.
    Ward, H.
    Lee, R.
    Rosenthal, E.
    Masur, H.
    Kottilil, S.
    Wilson, E. M. P.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S329 - S329
  • [36] A prospective, pragmatic post-authorisation safety study of early recurrence of hepatocellular carcinoma in hepatitis C virus-infected patients after direct-acting antiviral (DAA) therapy: DAA-PASS
    Singal, Amit
    Fried, Michael
    Colombo, Massimo
    Cabrera, Roniel
    Kelley, Katie
    Mehta, Neil
    Sangro, Bruno
    JOURNAL OF HEPATOLOGY, 2023, 78 : S1189 - S1189
  • [37] Protein Tyrosine Phosphatase Nonreceptor Type 2 Expression Does Not Correlate with Viral Load or Response to Direct-Acting Antiviral Therapy in Hepatitis C Virus Infections-Infected Patients
    Sabev, Max
    Blumel, Sena
    Lang, Silvia
    Gottier, Claudia
    Weber, Achim
    Mertens, Joachim
    Mullhaupt, Beat
    Scharl, Michael
    Spalinger, Marianne R.
    DIGESTION, 2021, 102 (03) : 453 - 461
  • [38] Direct-Acting Antiviral Agents Reduce the Risk of Malignant Transformation of Hepatobiliary Phase-Hypointense Nodule without Arterial Phase Hyperenhancement to Hepatocellular Carcinoma on Gd-EOB-DPTA-Enhanced Imaging in the Hepatitis C Virus-Infected Liver
    Shimizu, Yoshiaki
    Arai, Kuniaki
    Yamashita, Taro
    Yamashita, Tatsuya
    Shimakami, Tetsuro
    Kawaguchi, Kazunori
    Kitamura, Kazuya
    Sakai, Yoshio
    Mizukoshi, Eishiro
    Honda, Masao
    Kitao, Azusa
    Kozaka, Kazuto
    Kobayashi, Satoshi
    Kaneko, Shuichi
    LIVER CANCER, 2020, 9 (03) : 261 - 274
  • [39] Evaluation of Plasma miR-17-5p, miR-24-3p and miRNA-223-3p Profile of Hepatitis C Virus-Infected Patients after Treatment with Direct-Acting Antivirals
    Oksuez, Zehra
    Gragnani, Laura
    Lorini, Serena
    Temel, Guelhan Orekici
    Serin, Mehmet Sami
    Zignego, Anna Linda
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (08):
  • [40] PREDICTIVE VALUE OF THE INTERFERON-LAMBDA 4 GENE (IFN-L4) FOR DIRECT-/ANTIVIRAL TREATMENT IN HEPATITIS C VIRUS INFECTED PATIENTS WITH GENOTYPES 1, 2, 3, AND 4
    Susser, S.
    Lange, C. M.
    Hamdi, N.
    Berg, T.
    Perner, D.
    Zeuzem, S.
    Sarrazin, C.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S314 - S314
1234